Search

Dana-Farber Cancer Institute and Nadine Tung, Principal Investigator

Dana-Farber Cancer Institute and National Human Genome Research Institute (NHGRI)

F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer Institute

Stanford University, Northwestern University, MJHS Institute for Innovation in Palliative Care, Massachusetts General Hospital, City of Hope Medical Center, Dana-Farber Cancer Institute, New York Presbyterian Hospital, Odette Cancer Center - Sunnybrook Hospital, VA New York Harbor Healthcare System, University of Pennsylvania, Smilow Cancer Hospital - Yale New Haven Health, Department of Veterans Affairs, New Jersey, and Vidant Cancer Care

Peptomyc S.L., Osteosarcoma Institute, Curing Kids' Cancer Foundation, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Oregon Health and Science University

Boston Children's Hospital, University of Memphis, Monroe Carell Jr. Children's Hospital at Vanderbilt, Baylor College of Medicine, Children's Hospital of Philadelphia, and Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Johns Hopkins University, AstraZeneca, Dana-Farber Cancer Institute, and Nadine Tung, Prinicipal Investigator

Novartis, Dana-Farber Cancer Institute, and M.D. Anderson Cancer Center

National Institute of Nursing Research (NINR), Boston Children's Hospital, Dana-Farber Cancer Institute, University of Alabama at Birmingham, Deakin University, and Joanne Wolfe, MD, MPH, Physician in Chief, Chair, Department of Pediatrics

Dana-Farber Cancer Institute, Duke University, H. Lee Moffitt Cancer Center and Research Institute, and Hermioni L.Amonoo, MD, MPP, MPH, Director, Well-Being and Cancer Research Program

American Heart Association, Dana-Farber Cancer Institute, and Reza Nezafat, Principal Investigator

Celgene, Dana-Farber Cancer Institute, and Jacalyn Rosenblatt, Jacalyn Rosenblatt, MD

National Cancer Institute (NCI), Dana-Farber Cancer Institute, Ohio State University, University of Memphis, and University of Southern California

Sanofi and Dana-Farber Cancer Institute

H. Lee Moffitt Cancer Center and Research Institute, University of Southern California, Dana-Farber Cancer Institute, and Huntsman Cancer Institute

Daiichi Sankyo, GlaxoSmithKline, University of Nebraska, Ohio State University Comprehensive Cancer Center, The University of Texas Health Science Center, Houston, M.D. Anderson Cancer Center, University of Florida, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Gilead Sciences, and National Institute of Nursing Research (NINR)

University of Minnesota, Stanford University, Dana-Farber Cancer Institute, Vanderbilt University, Medical College of Wisconsin, Washington University School of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Memorial Sloan Kettering Cancer Center, and National Cancer Institute (NCI)

University of Chicago, University of Kansas, University of Pennsylvania, Johns Hopkins University, City of Hope National Medical Center, Loma Linda University, MedStar Georgetown, University of Arizona, University of Manitoba, University of Michigan, University of North Carolina, University of Pittsburgh, University of Rochester, Dana-Farber Cancer Institute, University of Wisconsin, Madison, The Cleveland Clinic, University of California, San Diego, Kaiser Permanente, Ohio State University, Virginia Mason Hospital/Medical Center, University of Alabama at Birmingham, and University of Miami

National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, Dana-Farber Cancer Institute, National Marrow Donor Program, and Emory University

Dana-Farber Cancer Institute, Children's Hospital Medical Center, Cincinnati, Children's Hospital Los Angeles, Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Baylor College of Medicine, Children's Hospital of Philadelphia, University of Wisconsin, Madison, Karolinska University Hospital, Hackensack Meridian Health, Duke University, Oslo University Hospital, Children's Mercy Hospital Kansas City, Mayo Clinic, University of Chicago, Massachusetts General Hospital, and Suneet Agarwal, Associate Professor of Pediatrics

Dana-Farber Cancer Institute

Rockefeller University, Flinders Medical Centre, University of Southern California, Gen-Probe, Incorporated, Genentech, Inc., General Electric, Purdue University, Biocept, Inc., Duke University, Ikonysis, Array Genomics, Cold Spring Harbor Laboratory, Nodality, Epic Sciences, Rutgers Cancer Institute of New Jersey, Dana-Farber Cancer Institute, Johns Hopkins University, M.D. Anderson Cancer Center, Oregon Health and Science University, University of California, San Francisco, University of Chicago, University of Michigan, University of Washington, University of Wisconsin, Madison, Fred Hutchinson Cancer Center, Broad Institute, Weill Medical College of Cornell University, Institute of Cancer Research, United Kingdom, Vitatex Inc., Serametrix Corporation, Promega Corporation, Creatv Microtech, Inc., Viatar LLC, Massachusetts Institute of Technology, Advanced Cell Diagnostics, ApoCell, Inc., Beckman Coulter GmbH, Bioview, Inc., Clearbridge BioMedics Pte Ltd., Singapore, Cynvenio Biosystems, Exosome Diagnostics, Inc., Fluxion Biosciences, Foundation Medicine, Universitätsklinikum Hamburg-Eppendorf, Brooklyn ImmunoTherapeutics, LLC, Ohio State University, Palo Alto Research Center, Rarecells, Silicon Biosystems, The Scripps Research Institute, University of Minnesota, Janssen Diagnostics, LLC, University of Regensburg, and Innocrin Pharmaceuticals Inc.

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute, Children's Hospital of Orange County, and University of Calgary

Children's National Research Institute, Dana-Farber Cancer Institute, Washington University School of Medicine, University of Texas Southwestern Medical Center, M.D. Anderson Cancer Center, Children's Hospital Colorado, Rutgers University, Massachusetts General Hospital, Klinikum Dortmund Wirbelsäulenchirurgie, ResourcePath, LLC, Allina Health System, Phoenix Children's Hospital, University of Cambridge, and Kris Ann Schultz, Kris Ann P. Schultz, MD, MS

National Institute for Biomedical Imaging and Bioengineering (NIBIB), Dana-Farber Cancer Institute, and Ellen Grant, Principal Investigator

National Cancer Institute (NCI), Northwestern University, Ohio State University, Dana-Farber Cancer Institute, Scripps Clinic, and Northwell Health

Dana-Farber Cancer Institute and Victor Wang, CEO

Dana-Farber Cancer Institute and David J. Einstein, Principal Investigator

Chimerix, Mithil Prasad Foundation, Storm the Heavens Fund, The ChadTough Defeat DIPG Foundation, National Cancer Institute (NCI), Dana-Farber Cancer Institute, and Sabine Mueller, MD, PhD, Principal Investigator

Massachusetts General Hospital, Dana-Farber Cancer Institute, GlaxoSmithKline, and Sophia Koo, M.D., Sponsor-Investigator

Dana-Farber Cancer Institute and Irving Kaplan, Principal Investigator

Agenus Inc., Dana-Farber Cancer Institute, and Bruno Bockorny, Principal Investigator

St. Jude Children's Research Hospital, University of Colorado, Denver, Dana-Farber Cancer Institute, and University of Chicago

City of Hope National Medical Center, Providence Cancer Center, Earle A. Chiles Research Institute, Dartmouth-Hitchcock Medical Center, Indiana University, Loyola University, Our Lady of Mercy Medical Center, Roswell Park Cancer Institute, University of California, Los Angeles, University of Cincinnati, University of Pittsburgh, University of Virginia, Vanderbilt University, Wayne State University, Dana-Farber Cancer Institute, and David McDermott, Principal Investigator

Dana-Farber Cancer Institute and Britni Ryan Belcher, PhD, MPH, Associate Professor

National Cancer Institute (NCI), Harvard School of Public Health (HSPH), Stanford University, Dana-Farber Cancer Institute, Fenway Community Health, and Andy Tan, Associate Professor

University of California, Los Angeles, Medical College of Wisconsin, Tufts Medical Center, Baylor College of Medicine, Johns Hopkins University, Dana-Farber Cancer Institute, Children's Hospital Los Angeles, and Mitchell Cairo, Principal Investigator

Dana-Farber Cancer Institute and Vanderbilt University Medical Center

Cogent Biosciences, Inc., Dana-Farber Cancer Institute, and The Life Raft Group

National Cancer Institute (NCI), University of Pennsylvania, University of Michigan, Dana-Farber Cancer Institute, Baylor College of Medicine, Fred Hutchinson Cancer Center, and Amit Singal, Professor

Radiological Society of North America, Dana-Farber Cancer Institute, and Vandana Dialani, Principal Investigator

Jazz Pharmaceuticals, Nationwide Children's Hospital, Dana-Farber Cancer Institute, University of California, San Francisco, University Hospitals Cleveland Medical Center, Duke University, and Sherwin Chan MD PhD, Physician, MD, PhD

University of Chicago, Dana-Farber Cancer Institute, Georgetown University, Johns Hopkins University, M.D. Anderson Cancer Center, University of Alabama at Birmingham, University of California, San Francisco, University of North Carolina, Duke University, Vanderbilt-Ingram Cancer Center, Indiana University Melvin and Bren Simon Cancer Center, Mayo Clinic, University of Pittsburgh Medical Center, and University of Michigan

Dana-Farber Cancer Institute and Chugai Pharma USA

Dana-Farber Cancer Institute and Stanford University

Janssen, LP, Baystate Health, Boston Medical Center, Dana-Farber Cancer Institute, Massachusetts General Hospital, Mayo Clinic, M.D. Anderson Cancer Center, Medical University of South Carolina, H. Lee Moffitt Cancer Center and Research Institute, Icahn School of Medicine at Mount Sinai, Northwell Health, Ochsner Health System, Ohio State University, Stanford University, Texas Medical Center, Thomas Jefferson University, University of Alabama at Birmingham, University of California, Los Angeles, University of Chicago, University of Colorado Health, University of Minnesota, University of New Mexico, University of Pennsylvania, University of Pittsburgh, University of Virginia, University of Washington, and Shruti Gupta, Associate Physician, Director of Onconephrology

Dana-Farber Cancer Institute, Massachusetts General Hospital, Weill Medical College of Cornell University, and City of Hope Comprehensive Cancer Center

Dana-Farber Cancer Institute